BCAL Diagnostics Limited (AU:BDX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BCAL Diagnostics Limited has issued over 7.3 million shares, including 3 million to its directors and 4.3 million to a director and employees, as part of their strategic growth initiatives. This move underlines the company’s ongoing efforts to solidify its financial standing while advancing its breast cancer diagnostic technology. BCAL Diagnostics aims to leverage its innovative non-invasive blood test to capture a significant share in the global breast cancer detection market.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.